- Details
- Petros Grivas elaborates on the structure, work, and initiatives of the ECOG-ACRIN Cooperative Group, emphasizing its diverse committees and its collaboration with the NCI. He highlights the Group's exploration of targeted therapies and non-immunotherapy combinations, especially through their innovative ComboMATCH program, designed to overcome resistance to single-agent targeted therapies. Grivas...
|
- Details
- In his discussion on PET imaging in genitourinary cancer, Stefano Fanti highlights the significance of PSMA in prostate cancer. He delves into the history of nuclear medicine as it pertains to prostate cancer, beginning with bone scans half a century ago and leading up to the emergence of PSMA-PET imaging. Biographies: Stefano Fanti, MD, Professor, Department of Experimental, Diagnostic and Specia...
|
- Details
- Umberto Capitanio discusses advancements in the treatment of kidney cancer over the past ten years. Dr. Capitanio mentions how surgical therapy was the only curative option for treating kidney cancer in 2012, but now there are multiple options available such as active surveillance, focal therapies, and stereotactic ablative body radiotherapy. Dr. Capitanio discusses how adjuvant therapy was not co...
|
- Details
- Philippe Spiess speaks about the Global Society of Rare GU Tumors. The society was founded by him and Andrea Necchi, who realized that rare cancers are underrepresented, particularly in clinical trials and peer-reviewed publications. The society's mission is to advance the care and management of rare GU tumors through global collaborations with the scientific community and patient advocacy. Biogra...
|
- Details
- Andrea Necchi presents recent advances in the treatment of bladder cancer. He highlights the significant contributions made by several prominent individuals in the field of genitourinary oncology, and discusses the recent progress in the development of immunotherapy for bladder cancer, with the FDA granting accelerated approval for the use of atezolizumab based on the evidence provided by phase II...
|
- Details
- Ewan Gibb, a PhD scientist, discusses the Decipher Bladder clinical test, a molecular subtyping assay for bladder cancer that predicts the risk of upstaging, identifies high-risk neuroendocrine-like disease and determines the benefit from neoadjuvant chemotherapy. The test breaks a patient's tumor into one of five subtypes and recognizes luminal and non-luminal categories, with neuroendocrine bein...
|
- Details
- Andrea Necchi joins Ashish Kamat to discuss the first edition of the San Raffaele Urologic Oncology retreat. The retreat aimed to bring together key opinion leaders worldwide to discuss potential collaborations and research projects in urological oncology. The retreat included presentations from local and external experts, including patient advocates, focusing on establishing international connect...
|
- Details
- Laura Marandino provides an update on trials enrolling patients with renal cell carcinoma at her institution, highlighting how the situation has changed significantly in the last 6 months. She begins with the non-metastatic renal cell carcinoma and M1 NED disease, discussing the KEYNOTE-564 trial that established a new standard of care in Europe and recent FDA and EMA approvals. However, she menti...
|
- Details
- Noel Clarke delivers a comprehensive discussion about the STAMPEDE trial model, focusing on its innovative approach to prostate cancer treatment in the UK. He elaborates on the multi-arm, multi-stage (MAMS) trial design, emphasizing its flexibility and efficiency, and the collaboration with large data sets like the National Prostate Cancer Audit. Dr. Clarke highlights significant results, such as...
|
- Details
- Marzia Del Re discusses the complexity of tumor heterogeneity in prostate cancer, focusing on predictive biomarkers of resistance and response to therapy. Dr. Del Re emphasizes the high heterogeneity of prostate cancer from clinical, morphological, and molecular perspectives, highlighting the role of genetic and epigenetic alterations. She explores technological advancements like next-generation s...
|
